Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Autism after high school: Making the transition

  • New technology shows promise for delivery of therapeutics to the brain

  • Higher suicide risk after served prison sentence

  • Major factor in development of Huntington's disease uncovered

  • Neglect of culture in medicine is 'single biggest barrier' to achieving better health

  • Different brain tumors have the same origin, new findings show

  • Politics can interact with evolution to shape human destiny

  • Heavy drinking in adolescence associated with lasting brain changes, animal study suggests

  • From age 8 to 80, expert reveals the price we pay for not sleeping

  • Evolution of competitiveness: Scientists explain diversity in competitiveness

  •